Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 1:45 AM
Ignite Modification Date:
2025-12-25 @ 1:45 AM
NCT ID:
NCT02863094
Eligibility Criteria:
Inclusion Criteria:
* Patients met diagnostic criteria for schizophrenia or schizoaffective disorder using the Structural Clinical Interview for Diagnostic and Statistical Manual Diploma in Social Medicine (DSM)-IV (SCID, Version 2.0),
* Patients reported auditory hallucinations at least 5 times per day based on pre-enrollment assessments using a written log or hand-held counter.
* Patients remain their psychotropic medication at steady dosages for at least 4 weeks prior to study entry and for the duration of the trial.
* Verbal intelligence quotient \> 85 as measured by using a Chinese version of the National Adult Reading Test.
Exclusion Criteria:
* History of significant head trauma or neurological disorders
* Alcohol or drug abuse
* Focal brain lesions on T1- or T2-weighted fluid-attenuated inversion-recovery magnetic resonance images
* a prior history of a seizure not induced by drug withdrawal,
* first degree relative with epilepsy, significant neurological illness or head trauma, endocrine disease, such as thyroid disease, significant unstable medical condition,
* recent aggression or other forms of behavioral dyscontrol
* left-handedness, pregnancy
* estimated intelligence quotient\<80
* current alcohol or drug abuse
* inability to provide informed consent.
* Hamilton Anxiety Rating Scale or the Hamilton Depression Rating Scale score \> 7
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
50 Years
Study:
NCT02863094
Study Brief:
Protocol Section:
NCT02863094